Favorable FDA briefing documents for Kythera's ATX-101

The Food and Drug Administration released briefing documents for Kythera Biopharmaceuticals Inc.'s (Nasdaq: KYTH) ATX-101 indicating a favorable benefit-risk assessment. The stock price leaped $10.10 to close at $50.00.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.